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Abstract
Background: Protection against pregnancy associated malaria (PAM) is associated with high levels of anti-VAR2CSA
antibodies. This protection is obtained by the parity dependent acquisition of anti-VAR2CSA antibodies. Distinct parity-
associated molecular signatures have been identified in VAR2CSA domains. These two observations combined point to the
importance of identifying VAR2CSA sequence variation, which facilitate parasitic evasion or subversion of host immune
response. Highly conserved domains of VAR2CSA such as DBL5e are likely to contain conserved epitopes, and therefore do
constitute attractive targets for vaccine development.
Methodology/Principal Findings: VAR2CSA DBL5e-domain sequences obtained from cDNA of 40 placental isolates were
analysed by a combination of experimental and in silico methods. Competition ELISA assays on two DBL5e variants, using
plasma samples from women from two different areas and specific mice hyperimmune plasma, indicated that DBL5e possess
conserved and cross-reactive B cell epitopes. Peptide ELISA identified conserved areas that are recognised by naturally
acquired antibodies. Specific antibodies against these peptides labelled the native proteins on the surface of placental
parasites. Despite high DBL5e sequence homology among parasite isolates, sequence analyses identified motifs in DBL5e that
discriminate parasites according to donor’s parity. Moreover, recombinant proteins of two VAR2CSA DBL5e variants displayed
diverse recognition patterns by plasma from malaria-exposed women, and diverse proteoglycan binding abilities.
Conclusions/Significance: This study provides insights into conserved and exposed B cell epitopes in DBL5e that might be a
focus for cross reactivity. The importance of sequence variation in VAR2CSA as a critical challenge for vaccine development is
highlighted. VAR2CSA conformation seems to be essential to its functionality. Therefore, identification of sequence variation
sitesindistinct locationswithinVAR2CSA, affectingantigenicityand/orbindingproperties,iscritical totheeffortof developing
an efficient VAR2CSA-based vaccine. Motifs associated with parasite segregation according to parity constitute one such site.
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Introduction
Women suffering from pregnancy-associated malaria (PAM)
develop antibodies that protect them and their offspring during
subsequent pregnancies [1]. Protection against PAM is rapidly
acquired as from the second pregnancy, and is associated with
increasing plasma levels of PAM-specific anti-Variant Surface
Antigen (VSA) antibodies. PAM parasites from distinct geographic
areas specifically bind Chondroitin-Sulfate A (CSA) [2,3,4], and the
immune response in pregnant women living in malariaendemic areas
is highly directed against var2csa encoded PfEMP1 (Plasmodium
falciparum erythrocyte membrane protein) protein [5,6,7]. Protective
antibodies in PAM immunity are thought to recognize a relatively
conserved antigen that mediatesparasite bindingto placental CSA, as
plasma and parasites from pregnant women of different malaria
endemic areas cross-react [5], [8]. Antibodies against VAR2CSA are
sex-specific and parity-dependent, and high levels of such antibodies
are associated with reduced consequences of PAM, making
VAR2CSA a promising target for vaccine development [6,7].
The VAR2CSA protein is a large antigenic molecule (350 kDa),
exposed to host antibodies on the surface of erythrocytes [9,10]. It
has been shown that disruption of var2csa results in the loss of CSA
adhesion ability of infected erythrocytes (IE) [11]. The VAR2CSA
protein is structurally composed of six Duffy Binding-Like (DBL)
domains. Several of these domains, including DBL5e, have, to
some extent, displayed affinity for CSA in vitro [12,13,14,15] [16].
Antibodies raised against CSA-binding VAR2CSA domains have
so far not been able to exhibit strong adhesion-inhibitory
PLoS ONE | www.plosone.org 1 October 2010 | Volume 5 | Issue 10 | e13105capabilities. However, antibodies raised against the recombinant
DBL5e domain amplified from a placental parasite, have been
shown to bind native VAR2CSA expressed on the surface of P.
falciparum IEs from placental isolates [16].
Var2csa is a polymorphic gene [17], and intra strain variability
represents a great challenge for vaccine development. In a previous
study, using genomic DNA from P. falciparum parasites from
Senegalese women, the DBL5e domain was found to be highly
conserved among parasite isolates [18]. Mapping on a structural
model revealed the localization of the DBL5e identified polymorphic
and some conserved regions in the exposed loops and helices [8,18].
Although most VAR2CSA DBL domains contain conserved and
polymorphic domain regions that can be targeted by surface reactive
antibodies [8], conserved regions are most prominent in DBL3X,
DBL4X and DBL5e. This may explain why antibodies raised against
DBL3X and DBL5e recombinant proteins exhibited most cross-
reactivity with heterologous parasites compared to antibodies raised
against the other domains [19]. Interestingly, these antibodies (raised
against a single variant of DBL3X or DBL5e) cross-reacted with
placental parasite isolates from Tanzania [20]. Moreover, human
monoclonal antibodies produced by immortalized B cells from
malaria-exposed pregnant women predominantly recognized DBL3X
and DBL5e [21], suggesting the natural acquisition of a specific
immune memory to these VAR2CSA domains.
Together, these observations highlight that DBL5e may
represent an interesting target for vaccine development. Under-
standing the molecular basis controlling the broad and/or
differential antibody recognition of this VAR2CSA domain may
help define essential structural features of a potential interest in
vaccine perspectives. The two main objectives of this study were:
(i) To analyse the consequence of sequence variation in the
VAR2CSA DBL5e domain using the transcripts from a large
panel of fresh placental parasite isolates and, (ii) to express and to
characterize selected VAR2CSA DBL5e variants from two
parasite isolates. Novel conserved linear epitopes which are
recognised by naturally acquired antibodies were found in the
conserved regions of the DBL5e domain and significant motifs
were identified in the variable regions.
Results
Identification of significant sites in VAR2CSA DBL5e
sequences
Figure 1 shows a multiple alignment of 70 VAR2CSA DBL5e
sequences (All sequence data are available at GenBank (http://
www.ncbi.nlm.nih.gov/Genbank) under the accession numbers
HM751723–HM751795) using cDNA from 40 placental parasites
isolated at delivery from 39 Senegalese women [2,15,22] and one
Figure 1. High conservation of DBL5e-VAR2CSA sequences. (A) Plot of DBL5e Shannon entropy (H): H=0: Complete conservation, only one
residue present at the given position. 0,H#1: Considered highly conserved. 1,H#2: Considered conserved. 2,H#4.3 considered variable. (B)
Three-dimensional model of DBL5e showing the sequence variability. Heat-map colouring is dark blue (conserved) to red (variable).
doi:10.1371/journal.pone.0013105.g001
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DBL5e plus Id5 (the non-DBL Interdomain sequence located
between DBL5e and DBL6e) was cloned and sequenced. A total of
70 VAR2CSA DBL5e sequences were obtained from these 40
placental parasites. The multiple alignment of DBL5e sequences
using the calculated Shannon entropy values show that the
sequences consist of constant and variable blocks (Figure S1,
Figure 1A). Conservation of 85% was obtained with DBL5e and
80% when we considered DBL5e plus Id5. The variability
mapping on the DBL5e structural model revealed that conserved
and variable areas were located in loops and protruding helices
(Figure 1B). In a previous study, it was found that VAR2CSA
DBL3X sequence motifs can be linked to the parity of the infected
women [15]. In order to assess such sequence variation behaviour
in another highly immunogenic and conserved VAR2CSA
domain, all DBL5e sequences generated from cDNA of PAM
isolates were analysed using SigniSite [23]. Analysis revealed that
certain amino acids of VAR2CSA DBL5e+Id5 sequences appear
to be of particular interest. In the multiple alignment of all DBL5e
sequences, significantly distributed residues were identified at
positions 277, 279, 303 (Fig 2A and 2B). High CSPG (Chondroitin
Sulphate Proteoglycan) binding density is correlated with amino
Figure 2. VAR2CSA DBL5e patterns distribution. (A, B): Sequence logo showing the identified significantly distributed residues I, K and Q The
sequence logo displays the residues present at each position, where at least one residue was identified as being significantly distributed with respect
to associated numerical parameter. Each letter denotes a given residue and the height corresponds to increasing z-score. The residues are coloured
according to: Acidic [ED]: red, Basic [RKH]: blue, Neutral [GNQSTY]=green, Hydrophobic [ACFILMPVW]=black. Numbers below each column denotes
corresponding position in the multiple alignment. Letters positioned correctly are associated with high values and upside down letters with low. An
asterisk denotes a deletion. It should be noted that in the sequence logos other residues appears (*, E, K), these are however not identified as
significantly distributed (i.e. p.0.05). DBL5e models showing the position of the identified significant residues (red), T277,I 279 (C) and Q303 (D).
doi:10.1371/journal.pone.0013105.g002
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furthermore revealed that identified residues that were significant-
ly different among groups were surface-exposed (Figure 2C,
Figure 2D).
From visual inspection of the regions around the amino acid
residues found by SigniSite analysis in the multiple alignment of
DBL5e, distinct motifs were identified when comparing sequences
from primigravidae and multigravidae. Motifs VFNNA, gap,
TFKNI were identified in the area spanning amino acids 275 to
279 and EDTKQ, EYTGN and QYTGN were defined between
theaminoacid 303and313(thisareaislocated at the endofDBL5e
andinId5). Thesepatternshave a differentialdistributionaccording
to parity. Indeed, gap, EDTKQ and EYTGN motifs were
predominantly found among samples from primigravidae
(p=0.02, Fisher’s exact test) whereas TFKNI and QYTGN were
mainly or exclusively found in multigravidae (p=0.013). These
patterns clearly discriminate parasites infecting multigravidae and
primigravidae women. At the level of sequence types obtained from
each sample, DBL5e sequences expressing gap, EDTKQ and
EYTGN signatures were found mostly in primigravidae (p=0.036)
while those expressing TFKNI (p=0.0019) and/or QYTGN
preferentially infect (p=0.038) multigravidae (Table 1). Interest-
ingly the TFKNI motif was also associated with high maternal age
and low placental parasite density (data not shown). The VFNNA
motif was found in primigravidae as well as multigravidae without
significant bias in its distribution. From the mapping of TFKNI and
deletion motifs on the DBL5e structural model from multigravidae
CYK008 sequence and primigravidae CYK040 respectively, it can
be hypothesised that TFKNI insertion can cause a conformational
change of the domain structure (Figure 3).
Expression of distinct variants of recombinant VAR2CSA
DBL5e from placental parasites
Two VAR2CSA DBL5e variants (CYK39 and CYK49) were
produced in Rosetta gami DE3 strains. Both variants were chosen for
analysis as P. falciparum IEs corresponding to isolate CYK39 have
beendescribed as high CSPG binders and parasites from CYK49 as
low binders [2]. The Rosettagami bacteria strain allows the formation
of disulfide bonds that could favour production of biologically active
proteins. Protein production was induced with 0.1 and 1 mM
IPTG. Thesolubleproteinproduced was affinity-purified,subjected
to gel filtration, and the purity was checked by SDS-PAGE
(Figure 4A) and Western blotting. An average of 5 mg of pure
protein was obtained after the different purification steps. Western
blot analysis showed that total IgG purified from a plasma pool of
malaria exposed multigravidae labelled a single dominant band of
37 kDa in 1 mM IPTG induced bacterial extract and in purified
DBL5e (Figure 4B). The same product (37 kDa) was identified by
specific IgG generated in mice by DNA vaccination with DBL5e_
CYK39 (Figure 4C) and DBL5e_ CYK49 IgG (Figure 4D), as well as
with anti-histidine tag monoclonal antibodies (Figure 4E). Bands of
expected size were observed neither in the untransformed nor
uninduced bacterial extracts (Figure 4).
In vitro binding ability of placental parasite recombinant
DBL5e VAR2CSA variants to CSPG
The CSPG binding capacity of the two DBL5e variants was
estimated by ELISA. Both variants showed a relatively higher
binding ability to CSPG compared to NTS-DBL1a domain of
VARO (Figure 5A). This interaction was concentration-depen-
dent. In this model, the NTS-DBL1a domain of VARO also
produced in Rosetta gami displayed weak binding ability to CSPG.
To determine whether this interaction was CSPG-specific, we
tested the ability of soluble CSPG (decorin) or CSA (bovine
trachea CSA) to compete for protein binding on a CSPG pre-
coated plate. As shown in Figure 5B, soluble CSPG like soluble
CSA (data not shown) indeed competed for binding observed on
CSPG. Sequence comparison of both DBL5e variants expressed
showed that they were highly similar but contained 31 different
residues. Moreover, positively charged amino acids appeared to be
differentially expressed in both variants (Figure 5C). As position
303 seemed to be associated with binding density, the sequences
were analysed for mean CSA and CSPG binding densities and the
difference associated with the occurrence of the Q, E and K
residues. Indeed, high CSA or CSPG binding affinity was mainly
associated with residue Q303 (p=0.005) whereas low CSA or
CSPG binding affinity was associated with E/K303 (Table 2).
Interestingly as shown in figure 5C, the equivalent residue for
CYK39 and CYK49 sequences was in fact Q296 and K296
respectively. The mapping of Q303 on structural model indicates
that this residue seems to be surface exposed, but located in the
bottom of what could be a binding pocket (Figure 2D).
Antibodies against DBL5e domain of VAR2CSA increase
in a parity-dependent manner
Recombinant DBL5e variants (CYK39 and CYK49) were used
to assess the plasma levels of anti-VAR2CSA IgG. Independent of
which variant was tested, antibodies with specificity for Rosetta gami-
produced DBL5e VAR2CSA were seen only in plasma from P.
falciparum-exposedpregnantwomenlivingeitherinBenin(Ben)orin
Table 1. Signatures in DBL5e domain of VAR2CSA expressed by placental parasites.
Category Parity VAR2CSA DBL5e motifs
VFNNA Gap TFKNI EDTKQ EYTGN QYTGN
Samples Primigravidae (n=16) 6 12
a 17
a 6
a 0
Multigravidae (n=24) 7 9 11
a 225
Sequences Primigravidae (n=33) 11 20
a 17
a 8
a 0
Multigravidae (n=37) 11 14 12 2 2 5
a
Gap, EDTKQ and EYTGN motifs are mainly found in samples from primigravidae compared to those from multigravidae (p=0.02) whereas TFKNI and QYTGN are mostly
or exclusively found in multigravidae (p=0.013). At the level of sequence types obtained from each sample, the EDTKQ, EYTGN and gap signatures are more frequent
among DBL5e sequences from primigravidae compared to those originating from multigravidae (p=0.036). Similarly, the TFKNI and QYTGN motifs are mostly or
exclusively found in sequences from multigravidae (p=0.0019 and p=0.038 respectively).
ap,.05, Fisher’s exact test.
bp,.001, Fisher’s exact test.
doi:10.1371/journal.pone.0013105.t001
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against the recombinant DBL5e were insignificant in both French
unexposed men (M) and pregnant women (Fra) (Figure 6A).
Detailed analysisofP. falciparum-exposed pregnant womenindicated
that for each antigen tested, Senegal and Benin multigravidae (M)
had significantly higher levels of DBL5e antibodies than primigrav-
idae (P); (CYK39: both p,0.0001; CYK49: p=0.019 for
Senegalese and p,0.0001 for Beninese; Figure 6B), however
contrary to Senegalese primigravidae, most Beninese primigravidae
presented with high DBL5e VAR2CSA antibody levels (Figure 6B).
A fine analysis of the plasma reactivity of the women demonstrates
that antibodies against DBL5e increased with parity (Figure 6C).
We compared plasma levels of VAR2CSA specific IgG using both
DBL5e recombinant proteins. Cut-off values were set to mean +
2SD (plus two standard deviations) of reading obtained with the
negative control plasma samples. The percentage of antibody
reactivity considered to be positive was 80% for DBL5e_CYK39
and 60% for DBL5e_CYK49. Despite a homology of 80%, there is
a significant difference of reactivity between both variants (Chi
2 test
p=0.005). A comparative study of the reactivity of each plasma
with respect to each of the variants shows that the response to both
variants was strongly correlated (Pearson’s test r=0.8, p,.0001;
Figure 6D), confirming that the VAR2CSA DBL5e domain
contained conserved epitopes.
Evidence of conserved cross-reactive epitopes in DBL5e
VAR2CSA
Recombinant DBL5e variants were used in competition ELISAs
to demonstrate that DBL5e domain of VAR2CSA contains cross-
Figure 3. Mapping of VAR2CSA-DBL5e signatures. Based on the
identified region of interest and predominant motifs, two representa-
tive sequences were selected for homology modelling primigravidae
CYK040 (deletion) and multigravidae CYK008 (TFKNI). Blue is CYK040
primigravidae sequence, red is CYK008 multigravidae sequence and
dotted circle is deletion/TFKNI motif. The figure illustrates how the
conformation of the region depends on the presence or absence of the
TFKNI-motif. Using homology modelling, the motif is identified as being
surface exposed and may thus alter the immunogenicity of the region.
doi:10.1371/journal.pone.0013105.g003
Figure 4. Bacterial recombinant DBL5e domain of VAR2CSA expression. Lysates of untransformed (lane 1) bacteria, DBL5e_CYK49
[uninduced (lane 2), induced 1mM IPTG (lane 3), induced 0.1 mM IPTG (lane 4)], DBL5e_CYK49 (lane 5) and DBL5e_CYK39 (lane 6) after two
purification steps were subjected to SDS/PAGE and either stained with Coomassie blue (A) or immunoblotted with either purified IgG multigravidae
plasma (B), antisera from mice vaccinated with DBL5e_CYK39 (C), antisera from DBL5e_CYK49 vaccinated mice (D) or monoclonal anti-histidine
antibodies (E). 30 mg of bacteria-expressed-extract proteins and 2 mg of purified domains were used for analysis. Immune complexes were detected
with appropriate horseradish peroxidase coupled antibodies.
doi:10.1371/journal.pone.0013105.g004
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VAR2CSA DBL5e was used for coating, the other one was used
as soluble competitor. The antibody reactivity of either a high-
titered VAR2CSA plasma pool from Beninese or Senegalese
women, or antisera to DBL5e_CYK39 and DBL5e_CYK49
generated in mice by DNA vaccination, or plasma pool from
unexposed French pregnant women was compared with or
without pre-incubation with increasing concentrations of the
competing VAR2CSA DBL5e variant. As negative control, all
plasma were incubated with VARO NTS-DBL1a domain.
Figure 7 shows that DBL5e from placental parasites contains
conserved epitopes. Indeed, whichever the DBL5e variant tested,
Figure 5. CSPG binding of the DBL5e domain of the VAR2CSA from parasite isolates. (A): Increasing concentrations of protein were added
to wells coated with 5 mg/ml of CSPG. CSPG-binding of the DBL5e_CYK39 (circle), DBL5e_CYK49 (triangle) and the non CSA-binding VARO NTS-DBL1a
domain used as control (square). Results are the means of three binding assays and the error bars indicate the standard deviation. (B) Inhibition assay.
Recombinant DBL5e variants (5 mg/ml) were pre-mixed with increasing amounts of soluble CSA 0.25–400 mg/ml, and binding to CSPG-coated plates
was determined. Results are the means of three inhibition binding assays and error bars indicate the standard deviation. (C): Sequence comparison of
VAR2CSA DBL5e domains from CYK39 and CYK49. Asterisks and circles indicate respectively Cystein residues and Lysine. Conserved amino acids are
shown in red and polymorphic residues in black. The 7 loops (L1–L7) identified according to Andersen P et al. [8] are underlined.
doi:10.1371/journal.pone.0013105.g005
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tion-dependant manner (Figure 7A). No significant competition
was seen with the negative VARO control protein (Figure 7B).
Due to the highly conserved nature of VAR2CSA DBL5e
sequence, it was decided to determine whether any of its conserved
regions was recognised by naturally acquired antibodies. We
synthesised a library of peptides using 3D7 DBL5e sequence. All
peptides were screened in ELISA for reactivity against a plasma
pool from Beninese or Senegalese women, French unexposed
pregnant women and men. Two peptides P4 and P13 located in
highly conserved regions of VAR2CSA displayed significant and
specific recognition by plasma of malaria exposed pregnant
women compared to control plasma from French unexposed
pregnant women and men (Kruskal-Wallis test, p,0.0001;
Figure 8A). Antibody reactivity of both peptides was higher in
multigravidae compared to primigravidae, though not significant
(Mann-Whitney U, p=0.17).
Specific antibodies to VAR2CSA DBL5e conserved
peptides mark native VAR2CSA on the surface of infected
erythrocyte
Mapping of both peptides P4 and P13 on DBL5e structural
model indicated that both of them are surface-exposed (Figure 8B).
Furthermore, specific antibodies against both peptides were
affinity-purified from the Senegalese pregnant women plasma
pool and allowed to react with PAM parasites collected from
pregnant women from Benin. The pregnancy specific antibody
recognition of the isolates used was checked prior by FACS with
human plasma control pools (data not shown). The results
presented on Figure 8C show that the antibodies with specificity
to the selected peptides reacted with the native VAR2CSA
expressed by PAM parasites on the surface of IE.
Discussion
Pregnant women acquire protective antibodies that cross-react
with geographically diverse placental P. falciparum isolates,
suggesting that surface molecules expressed on infected erythro-
cytes (IE) by PAM parasites have conserved epitopes and, thus,
that a PAM vaccine may be possible to achieve. The search for
surface antigens of placental P. falciparum parasites is focused on the
PfEMP1 family. Most studies in recent years have shown that
VAR2CSA is the dominant PfEMP1 associated with parasite
binding to the placenta. Due to technological difficulties the exact
conformation of the entire VAR2CSA protein remains unknown.
Preliminary studies to understand its binding properties focused on
its DBLs domains and functional studies have shown that several
VAR2CSA DBLs including DBL5e can individually bind CSA
in vitro. This approach has become questionable as no efficient
anti-adhesion antibodies for IE have been obtained following
vaccination with a single domain. Recent studies have nevertheless
demonstrated that VAR2CSA DBL5e domain can induce
antibodies with a broad range of reactivity against placental
isolates [16,20] and therefore may represent a potential target for
PAM vaccine development. This study analysed sequence
variation in the DBL5e domain of the transcribed var2csa gene
from multiple placental parasite isolates. The aim was to evaluate
antigenic diversity and diversifying pressure within this attractive
VAR2CSA area. Using cDNA (complementary acid deoxyribo-
nucleic) from 40 placental parasite isolates from a previous study,
the region encoding DBL5e+Id5 of var2csa was amplified, cloned
and sequenced. Findings from our study population clearly
confirmed previous observations that the VAR2CSA DBL5e is
highly conserved [18]. Indeed, an average of 81% amino-acid
sequence identity was seen among DBL5e sequences as reported
by Guitard et al. on a different study population [18]. Variations
were mainly located in segments of variable length and mapping of
DBL5e regions to 3-D model revealed that variable areas are
located in the loops and protruding helices [8].
Two variable regions, one in the DBL5e and another one in the
Id5 sequences appeared to be of particular interest regarding the
bias in motif distribution among gravid women. Three significant
motifs (gap, VFNNA and TFKNI) were identified in the first
region spanning Aa from position 275 to 279. Despite the
relatively high variability of the Id5, another area with motif
segregation (EDTKQ, EYTGN and QYTGN) was found between
Aa 303 and 313. The major observation in these sites is the
significant difference between motif occurrence among parasites
from primigravidae and multigravidae. Certain motifs are
preferentially found in parasites from primigravidae (gap275–279,
E303D308T309K312Q313 and E303Y308T309G312N313), whereas
others are only found in parasites infecting multigravidae
(TFKNI275–279 and QYTGN303–313). Interestingly, most of the
parasites with QYTGN303–313 motif also had TFKNI275–279.
Those expressing either EDTKQ303–313 or EYTGN303–313 are
mostly associated with a gap275–279. Such selection pattern was
already seen in the DBL3X sequence and plausible explanations
can be given, based on several hypotheses: (i) either that parasites
infecting primigravidae are the most efficient mediators for
binding and therefore have a biological advantage in women with
limited immunity against PAM, (ii) or that the parasite variants
mostly found in primigravidae are the more common in the area
and therefore are more likely to infect exposed primigravidae
while multigravid women already have developed specific
antibodies during previous pregnancies. The tropism of certain
parasite variants for multigravid women suggest that some rarer
variants, probably not the most virulent can escape existing
immunity to common VAR2CSA variants. These findings have
important implications for understanding immunity to PAM in a
context where the development of a VAR2CSA-based vaccine is
gaining interest. Further analyses in this study also found a
significant difference at a site situated in the Id5 according to the
ability of IE to bind CSA or CSPG in vitro. Isolates with high
binding affinities associated with Q303 and low CSA/CSPG
binders associated with E/K303. This could indicate that
conservation of Q303 may have conformational importance for
maintaining high binding ability by the IE.
The results generated in the present study highlight the fact that
fundamental gaps remain in our knowledge and understanding of
placental parasites. Protection against PAM is consistent with
repeated exposure during pregnancy to previously unknown
antigens. Most of multigravidae infected by parasites with the
TFKNI or QYTGN motifs have a parity status above 3,
Table 2. VAR2CSA-DBL5e residues Q303,E 303 and K303
distribution in relation to placental parasite CSA/CSPG
binding affinity.
Q303 E303 K303
Isolates
High binders (n=20) 10/20
a 6/20 6/20
Low binders (n=16) 1/16 7/16 9/16
Those parasites ability to bind CSA or CSPG have previously been described [2].
ap,.01, t-test.
n corresponds to placental parasite isolates.
doi:10.1371/journal.pone.0013105.t002
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pregnancies, women can still be infected by new parasite variants
[18]. In the context of developing an optimal VAR2CSA-based
vaccine that can protect against placental malaria, it will be
particularly useful to overcome the challenges associated to
sequence variation in this interesting candidate. The relation
underlying the even limited variations described in this study
suggests that these can have critical implication in the functionality
of the whole molecule including its ability to subvert immunity.
Our results clearly indicate that the design of a protective vaccine
based on VAR2CSA should not be limited to a single variant. A
limited number of variants may be sufficient for broad coverage,
provided sites under significant variations are considered.
We have characterized two distinct variants of DBL5e from our
study population. The measure of plasma levels of the antibodies
against these two DBL5e variants showed that the two proteins
were broadly recognized by samples from two malaria endemic
regions with different P. falciparum transmission levels. Both
VAR2CSA DBL5e variants were recognized in a parity-
dependent manner although the acquisition of immunity against
VAR2CSA differed between the two regions. In areas of intense P.
falciparum transmission, pregnant women generally develop
protective immunity to PAM over successive pregnancies, and
only primigravidae and secundigravidae present higher placental
infection prevalence rates [24]. In P. falciparum transmission areas
such as Benin, exposure is high and results in a fast acquisition of
Figure 6. Plasma reactivity against DBL5e domains of VAR2CSA. (A): Plasma levels of IgG with specificity for DBL5e domain of VAR2CSA in 8
French unexposed men (M), 16 French unexposed pregnant women (Fra), 75 Senegalese pregnant women (Sen) and 160 Beninese pregnant women
(Ben). DBL5e variants CYK39 and CYK49 were tested. (B): Plasma levels of VAR2CSA DBL5e domain according to parity. DBL5e antibodies levels were
quantified in the same groups of malaria-exposed pregnant women (Benin and Senegal) as in A. 24 primigravidae (P), 51 multigravidae (M) from
Senegal; 80 primigravidae and 80 multigravidae from Benin. (C): Plasma levels of VAR2CSA DBL5e domain according to parity range. Malaria exposed
women used in (B) were separated in three groups; primigravidae (P), women whose parity level is lower or equal to 3 (M#3) [Beninese women:
n=48, n=26 for Senegalese women] and those whose parity status is higher than 3 (M.3) [Beninese women: n=32, n=25 for Senegalese women].
(D) Correlation between the reactivity to each DBL5e variant in a given plasma.
doi:10.1371/journal.pone.0013105.g006
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PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e13105Figure 7. Cross-reactive antibody target between VAR2CSA DBL5e variants. Cross-reactivity was determined by competition ELISA using
either a multigravid plasma pool with high titer of VAR2CSA-specific antibodies (Beninese or Senegalese women), plasma from DBL5e_CYK39 or
CYK49 DNA genetic vaccinated mouse (A). NTS-DBL1a domain of VARO was used as negative control (B). Each colour shows the reactivity with the
indicated antibodies.
doi:10.1371/journal.pone.0013105.g007
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PLoS ONE | www.plosone.org 9 October 2010 | Volume 5 | Issue 10 | e13105Figure 8. Reactivity of human specific conserved DBL5e affinity purified antibodies with P. falciparum infected erythrocytes. (A): IgG
recognition of 3D7-DBL5e peptides library. (B): Mapping of P4 and P13 peptides on DBL5e model [8]. (C): Senegalese women antibodies were affinity
purified on peptides P4 and P13 and tested for reactivity against PAM Beninese parasite isolates. Flow cytometry analysis of human affinity-purified
IgG against peptides P4 and P13 against PAM parasite isolates. Each colour shows the reactivity to native parasites with the indicated antibodies. Four
isolates were tested with each IgG. Sample without primary antibody (blank), non-exposed women plasma pool, and exposed women plasma pool
are used as control respectively.
doi:10.1371/journal.pone.0013105.g008
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seasonal transmission such as in Senegal. In our two populations,
multigravidae presented with higher antibody levels against
VAR2CSA than primigravidae; but in Benin, where transmission
is perennial, the mean antibody level was overall higher than that
of women from Senegal. Among primigravidae, 57% of Beninese
had anti-VAR2CSA antibodies at delivery compared to 16% of
Senegalese. This could be explained by difference in malaria
exposure in the study areas. A close comparison of the two
VAR2CSA DBL5e recombinant variants demonstrated that,
despite a homology of 80% in their amino acid sequences, both
variants presented some distinguishable characteristics. The
DBL5e_CYK39 exhibited a higher CSPG binding ability and a
higher recognition by plasmas than the DBL5e_CYK49 variant,
although both constructs showed parity-dependent recognition
patterns. This observation suggests that some variants can be more
readily recognized than others. This can also be a useful
consideration in vaccine development strategy, as not all
VAR2CSA variants are likely to yield broad and high recognition
or reactivity.
In the variable regions of DBL5e distinct motifs were identified,
the sero-reactivity of peptide containing TFKNI (P19) was assessed
by ELISA. No reactivity was observed against this as shown in
Figure 8A. Nevertheless, this result is not surprising as we clearly
showed that TFKNI only were encountered in women presenting
high parity status and may be expressed by uncommon variants.
In the same effort to develop optimal VAR2CSA-based vaccine, it
is advisable to target highly conserved residues or as many residues
as possible that are accessible by host immune response to broaden
the possibility of reaching all potential parasite populations
expressing the VAR2CSA ligand. From the current observation
it is obvious that like DBL3X, the DBL5e domain variants share
common and cross-reactive motifs. We identified two peptides (P4
and P13) in the highly conserved region of the DBL5e domain that
significantly reacted with plasma pool from pregnant women of
different endemic areas. Affinity-purified antibodies against those
peptides specifically reacted with placental parasites, confirming
that these peptides are actually surface-exposed, as suggested by
the 3D model. One such epitope in DBL5e (peptide P63) was
previously described which reacted strongly with Tanzanian
female plasma [8]. DBL5e peptide P4 identified in this study has
16 amino acids out of 20 in common with P63 peptide. Existence
of such conserved and accessible epitopes supports the broad
recognition observed on this particular DBL domain and
emphasizes on its potential interest.
Knock-out studies have previously demonstrated the exclusive
need for VAR2CSA to mediate IE binding to CSA [11], and it has
been shown that four of the six Duffy-binding-like (DBL) domains
of VAR2CSA individually have the ability to bind CSA in vitro
[12,13,14,15,16], In this study, we confirmed the CSA-binding
ability of recombinant DBL5e to CSPG. Our results have
demonstrated in our experimental conditions, that both placental
isolate DBL5e variants have certain affinity for CSPG. This result
is in agreement with the fact that DBL5e _CYK39 variant is able
to bind to CSA and heparin sulfate [16]. However NTS-DBL1a
domain of the VARO PfEMP1 that is not involved in the placental
sequestration of parasites also presented a weak affinity to CSPG.
The binding of VAR2CSA to placental CSPG plays a major role
in malaria during pregnancy, and the understanding of this
interaction will be valuable to define easily producible constructs
that can induce adhesion inhibitory antibodies. Unlike CSA
binding that is unique to PAM parasites, in vitro interaction of
individual DBL with CSA is often seen with non-VAR2CSA
DBLs. Whether such interactions of individual domain can predict
for IE binding phenotype is debatable. Thus the CSPG interaction
was used in the current study only as an analytic tool to
characterize the properties of the both recombinant DBL5e
variants expressed. Recent studies have demonstrated that even
though DBL3X and DBL6e can bind to the same ligand, the sites
of interaction differ in these domains [25,26]. Nevertheless, in
each of these domains, the binding site involves residues that are
conserved in parasite isolates from different geographic locations.
We report in this study a difference in CSPG binding ability
among two VAR2CSA DBL5e variants. The structure of this
domain has not yet been solved and residues which are essential
for interaction are not identified.
In summary, we demonstrated for the first time that although
VAR2CSA DBL5e sequence has a limited antigenic diversity, it
contains some molecular signatures that distinguish parasites
according to the host parity. These findings have important
implications for vaccine design based on VAR2CSA. Malaria-
exposed women also develop antibodies against conserved parts of
VAR2CSA DBL5e domain. Two of such conserved epitopes were
identified here and, naturally acquired antibodies to them stained
native proteins on placental parasites. Our data support the
importance of DBL5e in the current effort of elucidating the parts
of the VAR2CSA protein that can induce an antibody response
with broad reactivity on placental parasites.
Materials and Methods
Parasite isolates
All P. falciparum PAM parasites for which sequences were
generated were collected at delivery in a cross-sectional study
conducted in Senegal in 2003[2]. Samples from 39 P. falciparum
isolates were available for the study. The mean 6 SD age of
women who donated the parasites was 2466.5 years. They were
composed of 15 primigravidae, 6 secundigravidae, and 18
multigravidae. P. falciparum infected erythrocytes (IEs) were
collected from parasitized placentas (parasite density ranging from
0.1% to 50%; mean 6 SD,12.8612.7) by flushing as previously
described [2]. Collected IEs were conserved in Trizol LS
(Invitrogen) and stored at 280uC until use. The binding ability
of parasite isolates to CSA were evaluated [2]. Neonate birth
weight was estimated by use of an electronic balance. There were
56% low birth weight LBW (,2500g) recorded.
Placental parasite ‘‘748’’ was collected in Tanzania, as described
elsewhere [20].
Parasites used to evaluate antibody reactivity with the surface of
IEs were freshly collected from pregnant women enrolled in the on
going STOPPAM project based in the district of Come `,
southwestern Benin [27].
Plasma samples collection
Plasma samples from malaria exposed women are from two
different malaria endemic areas: Perennial (Benin) and seasonal
(Senegal) P. falciparum transmission. Senegalese pregnant women
were enrolled in a cohort study in 2001 in Thiadiaye [7]. Women
presenting with fever and a positive blood smear were given
curative treatment with chloroquine, the drug advocated in
Senegal at the time of study for both prophylaxis and treatment.
In Benin, as described [28], pregnant women were enrolled in a
cohort study conducted from July 2005 through April 2008 in
Ouidah, a semirural town in Benin that is located 40 km west of
Cotonou, the political capital of Benin. Perennial malaria
transmission with seasonal peaks is mostly attributable to P.
falciparum [29]. Sulfadoxine-pyrimethamine or mefloquine was
given to women during the study.
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men without P. falciparum exposure were used as negative controls.
All women plasma samples tested in this study were collected at
delivery time.
Cloning and sequencing of placental var2csa DBL5e
genes
All VAR2CSA DBL5e sequences were obtained from placental
parasites complementary DNA (cDNA). Total RNA was extracted
from parasites conserved in Trizol according to the manufacturer’s
instruction. The total RNA concentration was determined at
260 nm and RNA integrity was checked in 1% agarose gel. RNA
samples were pretreated with DNAse I (Sigma-Aldrich). 5 U of
RNase-free DNase per 5 ug of RNA was incubated at 37uC for
30 min, followed by 10 min heat inactivation at 65uC. All RNA
samples were subsequently tested in real-time PCR for contam-
ination with genomic DNA using a primer set for the
housekeeping gene seryl-tRNA synthetase. cDNA was synthetised by
reverse trancriptase (Superscript II, Invitrogen) and random
hexamer primers, as described by the manufacturer. All
VAR2CSA DBL5e sequences were amplified using high fidelity
enzyme (Phusion) with the following universal primers designed in
highly conserved areas flanking the DBL5 DBL5e+the hypervari-
able interdomain (Id5): DBL5e Forward: 59-GTC ACC CCC
GGG GAC AAT GCA ATA AAA GAT TAC and DBL5e
Reverse: 59-TAG GCA TTT GCG GCC GCC TTC AAG TTC
AGC TGG AAT ATT. Two ml of cDNA was used for the PCR
reactions. PCR products were inserted into a pAcGP67C
Baculovirus Transfer Vector (BD). Ten to 15 colonies of each
cloning were sequenced by GATC (www.gatc.com).
Cloning, expression and purification of recombinant
VAR2CSA DBL5e variants proteins
DBL5e sequence from placental parasite isolate CYK 49 [2]
was amplified from the corresponding cDNA with the following
primers: 59 ACT GGC AGG AAT TCA TGT TTG ATG ATC
AGA CA and 39 ATC GAC TGG CAG GCG GCC GCT TAA
TGG TGA TGG TGA TGG TGT TTC ATA TCA TTA. PCR
product was digested with EcoR1 and Not1 for cloning into the
modified bacterial expression vector pET-21 (Novagen, http://
www.novagen.com) to produce His-tagged recombinant proteins
in Rosetta gami strain. The ligated vectors were transformed into E.
coli DH5a strain, and positive clones were selected with ampicillin
resistance. Rosetta gami cells transformed with recombinant
plasmids, were cultured into LB broth containing ampicillin
(50 mg/ml) at 30uC, and treated at the mid-log phase
(OD600=0.4) with IPTG, to induce protein production. Cells
were cultured at 25uC overnight, and harvested by centrifugation
at 6,000 g at 4uC for 15 min. The pellet was washed, resuspended
in cold buffer containing 10 mM Tris, 500 mM NaCl and
protease inhibitor cocktail (Cocktail set NuIII, Calbiochem), and
sonicated. DBL5e recombinant protein was purified from bacterial
soluble fraction on Ni
2+ metal-chelate agarose columns (GE
Healthcare), and eluted with 10 mM Tris, 500 mM NaCl and
150 mM imidazole. Affinity chromatography step was followed by
gel filtration. Recombinant DBL5e protein from isolate CYK 39
[16] and NTS-DBL1a VARO [30,31] were produced, and
purified under the same conditions.
Antibodies production
Specific antibodies to DBL5e CYK39 or DBL5e CYK49 were
induced in mice by genetic immunization. Briefly, DNA injections
were subcutaneously electro-transferred to 6-week-old Swiss
female mice (Janvier, France) using 40 mg of plasmid DNA
encoding either DBL5e_CYK39 or DBL5e_CYK49. All plasmids
used for genetic vaccination are based on a pVax1 vector back-
bone (Invitrogen) in which the original cytomegalovirus (CMV)
promoter has been replaced with the CMV promoter of the
pCMVb plasmid (Clontech), as described [32]. Mice were electro-
transferred on days 0, 21 and 45. Mice were bled before each
electroporation, and a full bleed was collected 80 days (D80) after
the first electroporation. Immune response was checked by ELISA
on consecutive bleeds. All procedures complied with European
and National regulations.
IgG from plasma of multigravidae living in an endemic area
were purified on a Hi-Trap protein G HP column according to the
manufacturer’s recommendations (GE-Healthcare). The specific-
ity of the purified antibodies was tested in ELISA against
recombinant DBL5e recombinant proteins (CYK39 and CYK49).
VAR2CSA proteins characterization by Western blotting
The soluble recombinant VAR2CSA DBL5e proteins were
checked by Sodium Dodecyl Sulfate-polyacrylamide gel electro-
phoresis and Western blotting. Protein samples (2–50 mg) were
suspended in Laemmli-buffer (Tris/HCl 62.5mM, pH6.8, 2%
SDS, 5% b-mercaptoethanol and 10% glycerol), subjected to
SDS-PAGE [33] using a 4–12% acrylamide slab minigel
(Invitrogen, Carisbad, CA, USA). Western blotting was performed
with (2–30 mg) bacterial (induced, uninduced and nontransformed)
lysates or purified eluates electrophoresed through 4–12% SDS-
PAGE gels and electro-transferred to 0.2 mm Protan BA 83
nitrocellulose sheets (Schleicher & Schuell) for immunodetection.
The membranes were blocked for 1 h with 5% nonfat dry milk in
phosphate-buffered saline (PBS) with 0.1% TweenH and then
incubated separately with either a 1:5000 dilution of a monoclonal
anti-histidine HRP conjugated antibody (46-0707, Invitrogen) or a
1:1000 dilution of DBL5e_CYK39 or DBL5e_CYK49 antiserum
from vaccinated mouse D50 (day 50) or 1:1000 of IgG purified
from plasma of multigravidae living in an endemic area. Immune
complexes were detected with a HRP coupled with either anti-
mouse IgG antibody (1:10 000, AP127P Sigma-Aldrich) or anti-
human IgG antibody (1:10 000, A0170 Sigma-Aldrich).
Competition ELISA, peptide ELISA and affinity
purification of antibodies
Prior to competition ELISA, both VAR2CSA DBL5e con-
structs were used to assess the plasma levels of anti VAR2CSA IgG
of 160 malaria exposed pregnant women from Benin (primigrav-
idae n=80, multigravidae n=80) and Senegal (primigravidae
n=24; multigravidae n=50), French unexposed pregnant women
(n=16), and French unexposed men (n=8). ELISA was carried
out on plates coated with 0.5 mg/ml of the DBL5e. The IgG
plasma levels were expressed as Optical densities (OD) values read
at 450nm. A pool of plasma samples from unexposed French
pregnant women was used as a negative control whereas a pool of
plasma samples from multigravidae pregnant Senegalese women,
previously demonstrated to have high levels of anti-VSA IgG
(VSA: Variant surface antigen) against placental isolates, was used
as a positive control.
For competition ELISA, microtiter plates (Nunc 442404) were
coated with each antigen (DBL5e_CYK39, DBL5e_CYK49,
NTS-DBL1a-VARO, 0.5 mg/ml in PBS). Five different plasma
pools were individually pre-incubated for 2 h at room temperature
(RT) with increasing concentrations of competing antigen (0.5, 1,
1.5, and 3 mg/ml): Beninese pregnant women plasma pool (diluted
1:500), Senegalese pregnant women plasma pool (diluted 1:500),
DBL5e_CYK39 plasma from DNA vaccinated D50 (1:100 000),
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and French unexposed women plasma pool (1:100). After
incubating the plates with blocking buffer (PBS, 0.5 M NaCl,
1% Triton X-100, 1% BSA) for 2 h at RT, the pre-absorbed pool
were added to the antigen-coated wells in duplicate and incubated
overnight at 4uC. In addition to the pre-absorbed plasma pool, a
non-absorbed pool was included for each coating antigen.
Following washing of the plates four times with washing buffer
(PBS, 0.5 M NaCl, 1% Triton X-100, pH 7.4), the secondary
antibody (Goat anti-human IgG HRP, A0170, Sigma-Aldrich for
human plasma and Goat anti-mouse IgG HRP, AP127P,
Chemicon) diluted 1:4000 in blocking buffer was added, and
incubated for 1 h at RT. Plates were washed four times, and
antibody reactivity visualized by the addition of TMB (Tetra-
methylbenzidine). Coloured reactions were stopped by the
addition of 0.5 M H2SO4 and OD was measured at 450 nm.
Peptides and antibodies affinity purification of antibodies
DBL5e of 3D7 PFL0030c var2csa sequence (Genbank accession
number. XM_001350379) was used to design peptides. A library
of 23 peptides (70% purity) each consisting of 20 amino acids and
having an overlap of 6 amino acids was synthesized (Sigma
Genosys). All peptides had a free amine at the N- and a free acid at
the OH-terminus. ELISA was carried out on plates coated with
5 mg/ml of each peptide. VAR2CSA antibodies reactivity against
those peptides was measured using Senegalese pregnant women
plasma pool 1:100 (pool was obtained with n=30 multigravidae
plasma) and Beninese pregnant women plasma pool 1:100 (pool
was obtained with n=30 multigravidae plasma). Plasma samples
from Unexposed French men (n=8) and pregnant women (n=16)
were used as negative controls.
The two peptides (P4: 2037RRQLCFSRIVRGPANLRNLK2056
and P13: 2163SWCTIPTTETPPQFLRWIKE2182) which reacted
with malaria exposed pregnant women plasma pool were used for
affinity purification of antibodies. This was done using HiTrap
NHS-activated HP columns (GE Healthcare) according to the
manufacturer’s instructions. In brief, 1 mg of each synthetic peptide
was dissolved in coupling buffer 0.2 M NaHCO3, 0.5 M NaCl
(pH 8.3), and applied to the 1 ml column previously equilibrated
with 362 ml of ice-cold 1 mM HCl. After coupling, the columns
were washed alternating 0.5 M ethanolamine, 0.5 M NaCl (pH 8.3)
and 0.1 M acetate, 0.5 M NaCl (pH 4), followed by a final wash
with PBS (pH 7.4). One ml of Senegalese pregnant women plasma
pool was diluted in PBS (1:1), filtered through a 0.45-mmf i l t e ra n d
applied to the column at a flow rate of 1 ml / min. After washing the
column in 7 ml PBS, affinity-bound antibodies were eluted in
fractions with a total volume of 3 ml of 0.1 M glycine-HCl (pH 2.8)
and neutralized in 1 M Tris (pH 8). The specificity of the purified
antibodies was tested in ELISA against the peptide used for affinity
purification.
Antibody recognition of surface VAR2CSA
P. falciparum-IEs collected ex vivo from the placenta of Beninese
women were used without additional in vitro culture. Flow
cytometry was used to test the reactivity of the antibodies against
either the P4 or P13 peptides with parasite isolates, as described
elsewhere [34]. Briefly, mature parasites (four placental isolates)
were enriched to contain .75% PE at late-stage trophozoite and
schizont stages by exposure to a strong magnetic field. Aliquots of
,2610
5 PE were labeled by ethidium bromide and sequentially
exposed to 20 ml human purified IgG (,0.2 mg IgG) and 1 ml goat
anti-human IgG-FITC (Sigma). Data were acquired using FACS
Calibur (BD Biosciences, Franklin 10 Lakes, NJ). All samples
relating to a particular parasite isolate were processed and
analyzed in a single assay.
Interaction properties of the recombinant DBL5e proteins
Binding to CSPG (decorin D8428, Sigma-Aldrich) was per-
formed mainly as described elsewhere [35]. Briefly falcon plates
(351172, Becton Dickinson) were coated with either 5 mg/ml
of CSPG in PBS or with 1% BSA in PBS for background
measurement (overnight at 4uC). Following coating, the wells were
blocked with TSM binding buffer (20 mM Tris–HCl, 90 mM
NaCl, 2 mMCaCl2, 2 mMMgCl2, 0.05%Tween-20 and 1%BSA,
pH 7.4 at 25uC) at room temperature for 6h. A dilution series
(0.4–40 mg/ml) of the DBL5e recombinant domains in TSM
binding buffer was added in each well and incubated overnight at
4uC with gentle shaking. After washing three times in TSM washing
buffer, 100 ml of anti-His tag-HRP antibody diluted 1:3 000 in
binding buffer was added to each well and incubated for 2h at room
temperature. The assay was finalised with three washes and
developed using 100 ml per well of TMB substrate for 30 min.
Absorbance was measured at 450 nm after quenching the reaction
with 100 ml of 0.5 M H2SO4.
Inhibition of recombinant domain binding to CSPG was
performed mainly as the above described ELISA analysis, but
using a constant protein concentration (5 mg/ml) pre-mixed with
increasing amounts of soluble CSA (0.5–400 mg/ml).
In silico analyses of VAR2CSA sequences from field
isolates
Multiple alignment. Initially a master data file was created,
containing sequence ids, experimental parameters (where
available) and unaligned sequences. The DBL5e were aligned
using ClustalW2 [36] with default options. The resulting
alignment was inspected and manually adjusted. Aligned
sequences were then inserted in the master file.
Evaluation of system diversity by calculation of Shannon
entropy. The Shannon entropy [37] was calculated for each
position in the multiple alignment as:
Hp ðÞ ~{
X
a
palog2 pa ðÞ
Briefly on values of H: H=0: Complete conservation, only one
residue present at the given position. 0,H#1: Considered highly
conserved. 1,H#2: Considered conserved. 2,H#4.3 considered
variable. The calculated Shannon Entropy per multiple alignment
position was subsequently depicted.
Homology modeling. DBL5e homology models were
created by submitting the multiple alignment to the HHpred
server [38]. Best hit was chosen based on an evaluation of score
and structure resolution (VAR2CSA DBL3x domain, PDB ID:
3bqk) [26]. One primi- and one multigravidae representative
sequence were chosen and submitted individually to HHpred. The
resulting models were loaded into PyMOL [39] and aligned for
visual analysis of structural impact of motifs. The models were
validated by submission to the ProQ server [40]. Likewise was a
model of DBL5e-3d7 created for mapping purposes.
Mapping of sequence variability. The sequence variability
was mapped onto a homology model of DBL5e-3d7 by submission
to the H2PDB server [41]. The resulting pdb-file was loaded into
PyMOL and variability was visualised by heat-map colouring
(colour by b-factor).
SigniSite analysis. A statistical In silico analysis of the
multiple alignment was performed using the SigniSite server
[23]. Briefly: The SigniSite server performs a non-parametric
VAR2CSA-DBL5e Domain Analysis
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position, aiming at identifying any significant association with a
sequence associated numerical parameter, specified at submission.
As a prerequisite for submission to SigniSite is the association of a
numerical parameter to each sequence, sequence files were created
for each numerical parameter containing the DBL5e sequences
and the associated numerical parameter (where available).
Numerical isolate parameters were: Maternal age at delivery
[year(s)], Concentration of parasites in peripheral blood of the
mother [/mL], Concentration of parasites in the placental blood
[/mL], Parity, Birth weight [g], CSA binding density [mean/
mm
2], CSPG binding density [mean/mm
2]. Some of the women
were infected with more than one parasite and thus some isolates
contain more than one sequence. It should be noted that (i)
numerical values associated with a particular isolate were assigned
to all the sequences identified in that particular isolate and (ii) not
all parameters were available for all sequences, if no parameter
was available, the sequence was excluded from evaluation. As
SigniSite performs multiple testing, it was imperative to reduce the
number of tests performed prior to submission. This was done in
two steps: (i) Exclusion of all positions in the multiple alignment
with H=0 (If just one residue is present at a given position, no
significant distribution is possible). (ii) Evaluating only the top 15%
most variable positions as estimated by the entropy calculation (It
is more likely to identify a significant distribution at the most
variable positions). Following this, the before mentioned sequence
files were reduced to only contain the positions selected for testing.
The sequence files were subsequently submitted to evaluation by
SigniSite with the following settings: Significance threshold=0.05,
Correction for multiple testing using the Bonferroni single-step,
Consider values given in fasta header and Choose decreasing
order. The normal distributed Z-scores were converted to p-values
by standard method.
Statistical analysis
Comparison of anti-VAR2CSA antibodies levels between
groups was tested by nonparametric Mann-Whitney test. Corre-
lations were examined by use of Pearson’s test. The chi
2 test was
used to examine differences between categorical variables. The
Fisher’s exact test was used to evaluate significance when analysing
motifs and parasite expressing specific motifs identified. The
significance limit was P,0.05. When evaluating DBL5e sequences
containing Q303 vs. E/K303, population means, with respect to
placental parasites CSA/CSPG binding, were calculated and a
two sample t-test was applied to test if differences in means were
significant (p,0.01).
Supporting Information
Figure S1 Multiple alignment of parasite isolates VAR2CSA
DBL5e sequences. cDNA from 40 placental parasites isolates (39
placental isolates from Senegal and one from Tanzania) were
amplified, cloned, and sequenced. Sequence ids are given at the
far left. The Tanzanian isolate was isolate 748 (sequences 748_1/
2a and 748_1/2b) corresponding to the DBL5e domain amplified
in this isolate. The remaining sequences correspond to those
obtained in isolates from Senegal. The remaining CYK are
Senegalese isolates. The CYK suffix corresponds to the placenta id
from which the isolate was extracted. The DBL5e and ID5 highly
conserved (blue, Shannon entropy 0#H#1), conserved (green,
1,H,1.5), and relatively variable (red, 1.5#H#2) blocks, are
indicated. The 15% most variable positions were selected and
marked with ‘‘x’’.
Found at: doi:10.1371/journal.pone.0013105.s001 (0.11 MB
PDF)
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